Related Experiment Video
Updated: May 19, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Plasma proteome-wide Mendelian randomization reveals multi-ancestry drug targets for gastric cancer
Peng Zhi1,2, Yan Cui1,2, Guanghui Xue1,2
1Experimental management center, Shanxi University of Chinese Medicine, Jinzhong, Shanxi, China.
Background:
Gastric cancer (GC) exhibits marked epidemiological differences between European (EUR) and East Asian (EAS) populations, with significantly higher incidence rates in EAS. Circulating proteins represent promising drug targets; however, most proteomic studies have focused primarily on EUR ancestry, leaving EAS-specific targets largely underexplored. This study aims to identify ancestry-specific plasma protein targets for GC using Mendelian randomization (MR).
Methods:
We employed Mendelian randomization (MR) and colocalization approaches to assess the putative causal effects of plasma proteins on GC risk across diverse populations. Specifically, we examined proteins in EUR and EAS populations. Subsequent single-cell RNA sequencing and molecular docking were conducted to identify cellular expression patterns and potential therapeutic compounds. Finally, experiments were conducted to verify the newly discovered drug target.
Results:
Our analyses revealed four significant protein targets in the EUR population (SLURP1, ANGPTL3, NME4, ANXA10) and nine in the EAS population (ICAM5, SMOC1, PSCA, SATB1, SCRG1, PTPRB, ISLR2, NCR3LG1, SELE) associated with GC susceptibility. These drug targets are mainly expressed in epithelial cells, and Pit mucous cells in gastric tumor tissue. Experimental validation indicated significant downregulation of NME4 and upregulation of ICAM5 in GC cell lines and tissue samples, suggesting potential tumor-suppressive and oncogenic functions, respectively. Moreover, molecular docking identified seven repurposable drugs, with digoxin demonstrating cross-ancestry therapeutic potential.
Conclusion:
Our findings delineate 13 ancestry-specific protein targets, including five novel candidates, thereby enhancing our understanding of GC pathogenesis. This study underscores the importance of ancestral diversity in informing drug development strategies for GC. Future research should focus on validating these targets and exploring their functional mechanisms further to translate these findings into clinical applications.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetics of Drug Metabolism: Overview
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...